Synthesis,18 F-Radiolabelling and Biological Characterization of Novel Fluoroalkylated Triazine Derivatives for in Vivo Imaging of Phosphodiesterase 2A in Brain via Positron Emission Tomography

Molecules

Volumn 20, Issue 6, 2015, Pages 9591-9615

  Schröder, Susann ^a   Wenzel, Barbara ^a   Deuther Conrad, Winnie ^a   Teodoro, Rodrigo ^a   Egerland, Ute ^b   Kranz, Mathias ^a   Scheunemann, Matthias ^a   Höfgen, Norbert ^b   Steinbach, Jörg ^a   Brust, Peter ^a  

^a INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^b Biocrea GmbH   (Germany)

Author keywords

Alzheimer's disease; Micellar hplc; PDE2A; Pet imaging in brain

Indexed keywords

CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 2; FLUORINE; PDE2A PROTEIN, HUMAN; PHOSPHODIESTERASE INHIBITOR; RADIOPHARMACEUTICAL AGENT; TRIAZINE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; AUTORADIOGRAPHY; BRAIN; CHEMISTRY; FEMALE; HUMAN; ISOTOPE LABELING; METABOLISM; MOUSE; NEUROIMAGING; PERMEABILITY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; RAT; SPRAGUE DAWLEY RAT; ULTRASTRUCTURE;

ANIMALS; AUTORADIOGRAPHY; BRAIN; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 2; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; ISOTOPE LABELING; MICE; NEUROIMAGING; PERMEABILITY; PHOSPHODIESTERASE INHIBITORS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; TRIAZINES;

EID: 84938342534     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules20069591     Document Type: Article

References (48)

1. Kelly, M.P.; Adamowicz, W.; Bove, S.; Hartman, A.J.; Mariga, A.; Pathak, G.; Reinhart, V.; Romegialli, A.; Kleiman, R.J. Select 3′,5′-cyclic nucleotide phosphodiesterases exhibit altered expression in the aged rodent brain. Cell Signal. 2014, 26, 383-397.
2. Bender, A.T.; Beavo, J.A. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol. Rev. 2006, 58, 488-520.
3. Gomez, L.; Breitenbucher, J.G. PDE2 inhibition: Potential for the treatment of cognitive disorders. Bioorg. Med. Chem. Lett. 2013, 23, 6522-6527.
4. Maurice, D.H.; Ke, H.; Ahmad, F.; Wang, Y.; Chung, J.; Manganiello, V.C. Advances in targeting cyclic nucleotide phosphodiesterases. Nat. Rev. Drug Discov. 2014, 13, 290-314.
5. Fajardo, A.; Piazza, G.; Tinsley, H. The role of cyclic nucleotide signaling pathways in cancer: Targets for prevention and treatment. Cancers 2014, 6, 436-458.
6. Lugnier, C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol. Ther. 2006, 109, 366-398.
7. Keravis, T.; Lugnier, C. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: Benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br. J. Pharmacol. 2012, 165, 1288-1305.
8. Wang, Z.Z.; Zhang, Y.; Zhang, H.T.; Li, Y.F. Phosphodiesterase: An interface connecting cognitive deficits to neuropsychiatric and neurodegenerative diseases. Curr. Pharm. Des. 2015, 21, 303-316.
9. Lakics, V.; Karran, E.H.; Boess, F.G. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 2010, 59, 367-374.
10. Van Staveren, W.C.G.; Steinbusch, H.W.M.; Markerink-van Ittersum, M.; Repaske, D.R.; Goy, M.F.; Kotera, J.; Omori, K.; Beavo, J.A.; de Vente, J. MRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J. Comp. Neurol. 2003, 467, 566-580.
11. Stephenson, D.T.; Coskran, T.M.; Wilhelms, M.B.; Adamowicz, W.O.; O'Donnell, M.M.; Muravnick, K.B.; Menniti, F.S.; Kleiman, R.J.; Morton, D. Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species. J. Histochem. Cytochem. 2009, 57, 933-949.
12. Zhang, C.; Yu, Y.; Ruan, L.; Wang, C.; Pan, J.; Klabnik, J.; Lueptow, L.; Zhang, H.T.; O'Donnell, J.M.; Xu, Y. The roles of phosphodiesterase 2 in the central nervous and peripheral systems. Curr. Pharm. Des. 2015, 21, 274-290.
13. Van Staveren, W.C.G.; Markerink-van Ittersum, M.; Steinbusch, H.W.M.; de Vente, J. The effects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat. Brain Res. 2001, 888, 275-286.
14. Suvarna, N.U.; O'Donnell, J.M. Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus. J. Pharmacol. Exp. Ther. 2002, 302, 249-256.
15. Blokland, A.; Schreiber, R.; Prickaerts, J. Improving memory: A role for phosphodiesterases. Curr. Pharm. Des. 2006, 12, 2511-2523.
16. Boess, F.G.; Hendrix, M.; van der Staay, F.J.; Erb, C.; Schreiber, R.; van Staveren, W.; de Vente, J.; Prickaerts, J.; Blokland, A.; Koenig, G. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 2004, 47, 1081-1092.
17. Reneerkens, O.A.; Rutten, K.; Bollen, E.; Hage, T.; Blokland, A.; Steinbusch, H.W.; Prickaerts, J. Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801. Behav. Brain Res. 2013, 236, 16-22.
18. Morita, H.; Murata, T.; Shimizu, K.; Okumura, K.; Inui, M.; Tagawa, T. Characterization of phosphodiesterase 2A in human malignant melanoma PMP cells. Oncol. Rep. 2013, 29, 1275-1284.
19. Drees, M.; Zimmermann, R.; Eisenbrand, G. 3?,5?-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. Cancer Res. 1993, 53, 3058-3061.
20. Abusnina, A.; Keravis, T.; Zhou, Q.; Justiniano, H.; Lobstein, A.; Lugnier, C. Tumour growth inhibition and anti-angiogenic effects using curcumin correspond to combined PDE2 and PDE4 inhibition. Thromb. Haemost. 2015, 113, 319-328.
21. Bernard, J.J.; Lou, Y.R.; Peng, Q.Y.; Li, T.; Lu, Y.P. PDE2 is a novel target for attenuating tumor formation in a mouse model of UVB-induced skin carcinogenesis. PLoS ONE 2014, 9, e109862.
22. Podzuweit, T.; Nennstiel, P.; Müller, A. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl)adenine. Cell Signal. 1995, 7, 733-738.
23. Biagi, G.; Giorgi, I.; Livi, O.; Pacchini, F.; Rum, P.; Scartoni, V.; Costa, B.; Mazzoni, M.R.; Giusti, L. Erythro- and threo-2-hydroxynonyl substituted 2-phenyladenines and 2-phenyl-8-azaadenines: Ligands for A1 adenosine receptors and adenosine deaminase. Farmaco 2002, 57, 221-233.
24. Boess, F.G.; Grosser, R.; Hendrix, M.; Koenig, G.; Niewoehner, U.; Schauss, D.; Schlemmer, K.H.; Schreiber, R.; van der Staay, F.J. Novel Substituted Imidazotriazines as PDE II Inhibitors. Patent WO 2002/050078 A1, 27 June 2002.
25. Masood, A.; Huang, Y.; Hajjhussein, H.; Xiao, L.; Li, H.; Wang, W.; Hamza, A.; Zhan, C.G.; O'Donnell, J.M. Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling. J. Pharmacol. Exp. Ther. 2009, 331, 690-699.
26. Xu, Y.; Pan, J.; Chen, L.; Zhang, C.; Sun, J.; Li, J.; Nguyen, L.; Nair, N.; Zhang, H.; O'Donnell, J.M. Phosphodiesterase-2 inhibitor reverses corticosterone-induced neurotoxicity and related behavioural changes via cGMP/PKG dependent pathway. Int. J. Neuropsychopharmacol. 2013, 16, 835-847.
27. Domek-Łopacińska, K.; Strosznajder, J.B. The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Res. 2008, 1216, 68-77.
28. Rutten, K.; Prickaerts, J.; Hendrix, M.; van der Staay, F.J.; Şik, A.; Blokland, A. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: Studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. Eur. J. Pharmacol. 2007, 558, 107-112.
29. Abarghaz, M.; Biondi, S.; Duranton, J.; Limanton, E.; Mondadori, C.; Wagner, P. Benzo[1,4]diazepin-2-one Derivatives as Phosphodiesterase PDE2 Inhibitors, Preparation and Therapeutic Use Thereof. Patent WO 2005/063723 A1, 14 July 2005.
30. Dost, R.; Egerland, U.; Grunwald, C.; Höfgen, N.; Langen, B.; Lankau, H.J.; Stange, H. (1,2,4)Triazolo[4,3-a]quinoxaline Derivatives as Inhibitors of Phosphodiesterases. Patent WO 2012/104293 A1, 09 August 2012.
31. Andres, J.I.; Buijnsters, P.; de Angelis, M.; Langlois, X.; Rombouts, F.; Trabanco, A.A.; Vanhoof, G. Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors. Bioorg. Med. Chem. Lett. 2013, 23, 785-790.
32. Helal, C.J.; Chappie, T.A.; Humphrey, J.M.; Verhoest, P.R.; Yang, E. Imidazo[5,1-f][1,2,4]triazines for the Treatment of Neurological Disorders. U.S. Patent WO 2012/114222 A1, 23 August 2012.
33. Schmidt, B.; Weinbrenner, S.; Flockerzi, D.; Kuelzer, R.; Tenor, H.; Kley, H.P. Triazolophthalazines. Patent WO 2006/024640 A2, 09 March 2006.
34. Flockerzi, D.; Kley, H.P.; Kuelzer, R.; Schmidt, B.; Tenor, H.; Weinbrenner, S. Triazolophthalazines as PDE2-inhibitors. Patent WO 2006/072612 A2, 13 July 2006.
35. De Leon, P.; Egbertson, M.; Hills, I.D.; Johnson, A.W.; Machacek, M. Quinolinone PDE2 Inhibitors. U.S. Patent WO 2011/011312 A1, 27 January 2011.
36. Andres, J.I.; Rombouts, F.J.R.; Trabanco, A.A.; Vanhoof, G.C.P.; de Angelis, M.; Buijnsters, P.J.J.A.; Guillemont, J.E.G.; Bormans, G.M.R.; Celen, S.J.L. 1-Aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Derivatives. Patent WO 2013/000924 A1, 03 January 2013.
37. Zhang, L.; Villalobos, A.; Beck, E.M.; Bocan, T.; Chappie, T.A.; Chen, L.; Grimwood, S.; Heck, S.D.; Helal, C.J.; Hou, X.; et al. Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand. J. Med. Chem. 2013, 56, 4568-4579.
38. Stange, H.; Langen, B.; Egerland, U.; Hoefgen, N.; Priebs, M.; Malamas, M.S.; Erdel, J.J.; Ni, Y. Triazine Derivatives as Inhibitors of Phosphodiesterases. Patent WO 2010/054253 A1, 14 May 2010.
39. 18F-labeled radiotracers for neuroreceptor imaging with positron emission tomography. Neurosci. Bull. 2014, 30, 777-811.
40. Malamas, M.S.; Ni, Y.; Erdei, J.; Stange, H.; Schindler, R.; Lankau, H.J.; Grunwald, C.; Fan, K.Y.; Parris, K.; Langen, B.; et al. Highly potent, selective, and orally active phosphodiesterase 10A inhibitors. J. Med. Chem. 2011, 54, 7621-7638.
41. 18 F]fluoroethoxy)-6-methoxypyrrolidinylquinazoline for imaging of phosphodiesterase 10A with PET. Pharmaceuticals 2012, 5, 169-188.
42. Zhu, J.; Yang, Q.; Dai, D.; Huang, Q. X-ray crystal structure of phosphodiesterase 2 in complex with a highly selective, nanomolar inhibitor reveals a binding-induced pocket important for selectivity. J. Am. Chem. Soc. 2013, 135, 11708-11711.
43. 18F-β-carboline alkaloids as PET ligands. J. Label. Compd. Rad. 2008, 51, 277-282.
44. Nakao, R.; Schou, M.; Halldin, C. Direct plasma metabolite analysis of positron emission tomography radioligands by micellar liquid chromatography with radiometric detection. Anal. Chem. 2012, 84, 3222-3230.
45. Rambla-Alegre, M. Basic principles of MLC. Chromatogr. Res. Int. 2012, 2012, doi:10.1155/2012/898520.
46. 18F-FECNT: A polar radiometabolite confounds brain radioligand measurements. J. Nucl. Med. 2006, 47, 520-527.
47. Evens, N.; Vandeputte, C.; Muccioli, G.G.; Lambert, D.M.; Baekelandt, V.; Verbruggen, A.M.; Debyser, Z.; van Laere, K.; Bormans, G.M. Synthesis, in vitro and in vivo evaluation of fluorine-18 labelled FE-GW405833 as a PET tracer for type 2 cannabinoid receptor imaging. Bioorg. Med. Chem. 2011, 19, 4499-4505.
48. Burns, D.H.; Chan, H.K.; Miller, J.D.; Jayne, C.L.; Eichhorn, D.M. Synthesis, modification, and characterization of a family of homologues of exo-calix[4]arene: Exo-[n.m.n.m]metacyclophanes, n,m ≥ 3. J. Org. Chem. 2000, 65, 5185-5196.